HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm's Attorneys, Securities Class Action FiledPRNewsWire • 08/15/22
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KRBPNewsfile Corp • 08/13/22
Kiromic Biopharma, Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)Business Wire • 08/12/22
EQUITY ALERT: Rosen Law Firm Encourages Kiromic BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – KRBPBusiness Wire • 08/10/22
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)Business Wire • 08/10/22
KIROMIC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 08/10/22
Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific OfficerBusiness Wire • 07/12/22
Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology PipelineBusiness Wire • 07/07/22
Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product CandidateBusiness Wire • 06/21/22
Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research AgreementBusiness Wire • 06/07/22
Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsBusiness Wire • 05/13/22
Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022Business Wire • 05/11/22
Kiromic BioPharma Announces Availability of Company's Current Corporate PresentationBusiness Wire • 04/11/22
Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate HighlightsBusiness Wire • 04/08/22
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma, Inc. (KRBP) Investors to Investigation of Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm's AttorneysNewsfile Corp • 03/31/22
Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial ResultsBusiness Wire • 03/11/22
